OBJECTIVE: Variation in the interferon regulatory factor 5 (IRF5) gene has been associated with risk of developing systemic lupus erythematosus (SLE), and this association is largely dependent upon anti-Ro autoantibodies. This study was undertaken to determine if the IRF5 genotype is associated with maternal diagnosis or progression of autoimmunity. METHODS: Genotyping of haplotype-tagging polymorphisms in IRF5 was performed in 93 subjects of European ancestry who were recruited to the Research Registry for Neonatal Lupus. All subjects had high-titer anti-Ro autoantibodies and had a child with neonatal lupus (NL); allele frequencies were compared to those in nonautoimmune controls. The mothers had SLE, Sjögren's syndrome (SS), or undifferentiated autoimmune syndrome (UAS), or were asymptomatic. RESULTS: The SLE risk haplotype of IRF5 was enriched in all anti-Ro-positive subjects except in those with SS (odds ratio [OR] 2.55, P = 8.8 × 10(-4) ). The SLE risk haplotype was even enriched in asymptomatic individuals with anti-Ro antibodies (OR 2.69, P = 0.019). The same haplotype was more prevalent in subjects who were initially asymptomatic but developed symptomatic SLE during followup (OR 5.83, P = 0.0024). Interestingly, SS was associated with 2 minor IRF5 haplotypes, and these same haplotypes were decreased in frequency in mothers with SLE and those with UAS. CONCLUSION: The IRF5 SLE risk haplotype was associated with anti-Ro antibody positivity in asymptomatic individuals, as well as with progression to SLE in asymptomatic anti-Ro-positive individuals. SS in mothers of children with NL was associated with different IRF5 haplotypes. These data suggest that IRF5 polymorphisms play a role in serologic autoimmunity in humans and may promote the progression to clinical autoimmunity.
OBJECTIVE: Variation in the interferon regulatory factor 5 (IRF5) gene has been associated with risk of developing systemic lupus erythematosus (SLE), and this association is largely dependent upon anti-Ro autoantibodies. This study was undertaken to determine if the IRF5 genotype is associated with maternal diagnosis or progression of autoimmunity. METHODS: Genotyping of haplotype-tagging polymorphisms in IRF5 was performed in 93 subjects of European ancestry who were recruited to the Research Registry for Neonatal Lupus. All subjects had high-titer anti-Ro autoantibodies and had a child with neonatal lupus (NL); allele frequencies were compared to those in nonautoimmune controls. The mothers had SLE, Sjögren's syndrome (SS), or undifferentiated autoimmune syndrome (UAS), or were asymptomatic. RESULTS: The SLE risk haplotype of IRF5 was enriched in all anti-Ro-positive subjects except in those with SS (odds ratio [OR] 2.55, P = 8.8 × 10(-4) ). The SLE risk haplotype was even enriched in asymptomatic individuals with anti-Ro antibodies (OR 2.69, P = 0.019). The same haplotype was more prevalent in subjects who were initially asymptomatic but developed symptomatic SLE during followup (OR 5.83, P = 0.0024). Interestingly, SS was associated with 2 minor IRF5 haplotypes, and these same haplotypes were decreased in frequency in mothers with SLE and those with UAS. CONCLUSION: The IRF5SLE risk haplotype was associated with anti-Ro antibody positivity in asymptomatic individuals, as well as with progression to SLE in asymptomatic anti-Ro-positive individuals. SS in mothers of children with NL was associated with different IRF5 haplotypes. These data suggest that IRF5 polymorphisms play a role in serologic autoimmunity in humans and may promote the progression to clinical autoimmunity.
Authors: Corinna E Weckerle; Beverly S Franek; Jennifer A Kelly; Marissa Kumabe; Rachel A Mikolaitis; Stephanie L Green; Tammy O Utset; Meenakshi Jolly; Judith A James; John B Harley; Timothy B Niewold Journal: Arthritis Rheum Date: 2011-04
Authors: Timothy B Niewold; Jennifer A Kelly; Silvia N Kariuki; Beverly S Franek; Akaash A Kumar; Kenneth M Kaufman; Kenaz Thomas; Daniel Walker; Stan Kamp; Jacqueline M Frost; Andrew K Wong; Joan T Merrill; Marta E Alarcón-Riquelme; Mohammed Tikly; Rosalind Ramsey-Goldman; John D Reveille; Michelle A Petri; Jeffrey C Edberg; Robert P Kimberly; Graciela S Alarcón; Diane L Kamen; Gary S Gilkeson; Timothy J Vyse; Judith A James; Patrick M Gaffney; Kathy L Moser; Mary K Crow; John B Harley Journal: Ann Rheum Dis Date: 2011-11-16 Impact factor: 19.103
Authors: Christophe Richez; Kei Yasuda; Ramon G Bonegio; Amanda A Watkins; Tamar Aprahamian; Patricia Busto; Rocco J Richards; Chih Long Liu; Regina Cheung; Paul J Utz; Ann Marshak-Rothstein; Ian R Rifkin Journal: J Immunol Date: 2009-12-09 Impact factor: 5.422
Authors: G Nordmark; G Kristjansdottir; E Theander; P Eriksson; J G Brun; C Wang; L Padyukov; L Truedsson; G Alm; M-L Eloranta; R Jonsson; L Rönnblom; A-C Syvänen Journal: Genes Immun Date: 2008-12-18 Impact factor: 2.676
Authors: T L Rivera; P M Izmirly; B K Birnbaum; P Byrne; J B Brauth; M Katholi; M Y Kim; J Fischer; R M Clancy; J P Buyon Journal: Ann Rheum Dis Date: 2008-07-14 Impact factor: 19.103
Authors: Robert R Graham; Chieko Kyogoku; Snaevar Sigurdsson; Irina A Vlasova; Leela R L Davies; Emily C Baechler; Robert M Plenge; Thearith Koeuth; Ward A Ortmann; Geoffrey Hom; Jason W Bauer; Clarence Gillett; Noel Burtt; Deborah S Cunninghame Graham; Robert Onofrio; Michelle Petri; Iva Gunnarsson; Elisabet Svenungsson; Lars Rönnblom; Gunnel Nordmark; Peter K Gregersen; Kathy Moser; Patrick M Gaffney; Lindsey A Criswell; Timothy J Vyse; Ann-Christine Syvänen; Paul R Bohjanen; Mark J Daly; Timothy W Behrens; David Altshuler Journal: Proc Natl Acad Sci U S A Date: 2007-04-05 Impact factor: 11.205
Authors: Dan Li; Bharati Matta; Su Song; Victoria Nelson; Kirsten Diggins; Kim R Simpfendorfer; Peter K Gregersen; Peter Linsley; Betsy J Barnes Journal: JCI Insight Date: 2020-01-30